首页 > 最新文献

Asia-Pacific Journal of Ophthalmology最新文献

英文 中文
Misdiagnosed ocular perforating injury with direct traumatic optic neuropathy from gun pellet confirmed intraoperatively. 术中证实枪丸致直接外伤性视神经病变的眼穿孔损伤误诊。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-16 DOI: 10.1016/j.apjo.2025.100246
Thibaud Garcin, Mathilde Kaspi, Nacim Bouheraoua, Vincent Borderie
{"title":"Misdiagnosed ocular perforating injury with direct traumatic optic neuropathy from gun pellet confirmed intraoperatively.","authors":"Thibaud Garcin, Mathilde Kaspi, Nacim Bouheraoua, Vincent Borderie","doi":"10.1016/j.apjo.2025.100246","DOIUrl":"10.1016/j.apjo.2025.100246","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":" ","pages":"100246"},"PeriodicalIF":4.5,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence. 西马鲁肽会增加非动脉性前缺血性视神经病变的风险吗?对新出现的证据进行系统回顾和荟萃分析。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-15 DOI: 10.1016/j.apjo.2025.100245
Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan

Background: Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently been linked to rare ocular adverse events, including non-arteritic anterior ischemic optic neuropathy (NAION). Given the growing concerns and limited clarity, this systematic review and meta-analysis aims to critically assess the potential association between semaglutide use and NAION risk.

Objectives: To evaluate the association between semaglutide use and the development of NAION.

Methods: A comprehensive literature search was conducted via different databases from inception to June 3rd, 2025. A reviewer screened the potential articles against prespecified eligibility criteria. The risk of bias in the eligible studies was then evaluated using the Newcastle Ottawa Scale (NOS). Data were then systematically extracted and analyzed.

Results: The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study. Semaglutide use was associated with a significantly increased risk of NAION compared to control medications, with a pooled hazard ratio of 2.620 (95 % CI: 1.808-3.795, P < 0.001). Risk elevation showed time-dependency, becoming statistically significant after 2 years of exposure. Identified risk factors included older age, male sex, prolonged diabetes duration, elevated HbA1c, diabetic retinopathy, and obesity. Among GLP-1 receptor agonists, semaglutide accounted for 86.5 % of reported NAION cases. Clinical presentations featured optic disc edema, intraretinal fluid on OCT, and crowded optic discs. Cumulative incidence rates were substantially higher in semaglutide users versus non-GLP-1 receptor agonist comparators.

Conclusions: Semaglutide use shows association with increased NAION risk, particularly with prolonged exposure and in patients with predisposing factors. Risk-benefit assessment and targeted ophthalmologic monitoring are recommended while maintaining appropriate therapeutic use.

背景:Semaglutide是一种广泛用于2型糖尿病和肥胖的GLP-1受体激动剂,最近被发现与罕见的眼部不良事件有关,包括非动脉性前缺血性视神经病变(NAION)。鉴于越来越多的关注和有限的清晰度,本系统综述和荟萃分析旨在批判性地评估使用西马鲁肽与NAION风险之间的潜在关联。目的:评价西马鲁肽的使用与NAION的发展之间的关系。方法:在不同数据库中检索自成立至2025年6月3日的文献。审稿人根据预先规定的资格标准筛选潜在的文章。然后使用纽卡斯尔渥太华量表(NOS)评估符合条件的研究的偏倚风险。然后系统地提取和分析数据。结果:数据库检索得到225条记录,其中10篇关于Semaglutide与NAION相关性的研究文章被纳入本研究。与对照药物相比,使用Semaglutide与NAION的风险显著增加相关,合并风险比为2.620 (95% CI: 1.808-3.795, P < 0.001)。风险升高表现出时间依赖性,暴露2年后具有统计学意义。确定的危险因素包括年龄较大、男性、糖尿病病程延长、糖化血红蛋白升高、糖尿病视网膜病变和肥胖。在GLP-1受体激动剂中,西马鲁肽占报告的NAION病例的86.5%。临床表现为视盘水肿,OCT显示视网膜内积液,视盘拥挤。与非glp -1受体激动剂比较剂相比,semaglutide使用者的累积发病率要高得多。结论:Semaglutide的使用与NAION风险增加有关,特别是长时间暴露和有易感因素的患者。在保持适当的治疗使用的同时,建议进行风险-效益评估和有针对性的眼科监测。
{"title":"Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.","authors":"Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan","doi":"10.1016/j.apjo.2025.100245","DOIUrl":"10.1016/j.apjo.2025.100245","url":null,"abstract":"<p><strong>Background: </strong>Semaglutide, a GLP-1 receptor agonist widely prescribed for type 2 diabetes and obesity, has recently been linked to rare ocular adverse events, including non-arteritic anterior ischemic optic neuropathy (NAION). Given the growing concerns and limited clarity, this systematic review and meta-analysis aims to critically assess the potential association between semaglutide use and NAION risk.</p><p><strong>Objectives: </strong>To evaluate the association between semaglutide use and the development of NAION.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted via different databases from inception to June 3rd, 2025. A reviewer screened the potential articles against prespecified eligibility criteria. The risk of bias in the eligible studies was then evaluated using the Newcastle Ottawa Scale (NOS). Data were then systematically extracted and analyzed.</p><p><strong>Results: </strong>The database search yielded 3539 records, of which 10 research articles investigating the association between Semaglutide and NAION were included in this study. Semaglutide use was associated with a significantly increased risk of NAION compared to control medications, with a pooled hazard ratio of 2.620 (95 % CI: 1.808-3.795, P < 0.001). Risk elevation showed time-dependency, becoming statistically significant after 2 years of exposure. Identified risk factors included older age, male sex, prolonged diabetes duration, elevated HbA1c, diabetic retinopathy, and obesity. Among GLP-1 receptor agonists, semaglutide accounted for 86.5 % of reported NAION cases. Clinical presentations featured optic disc edema, intraretinal fluid on OCT, and crowded optic discs. Cumulative incidence rates were substantially higher in semaglutide users versus non-GLP-1 receptor agonist comparators.</p><p><strong>Conclusions: </strong>Semaglutide use shows association with increased NAION risk, particularly with prolonged exposure and in patients with predisposing factors. Risk-benefit assessment and targeted ophthalmologic monitoring are recommended while maintaining appropriate therapeutic use.</p>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":" ","pages":"100245"},"PeriodicalIF":4.5,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperreflective foci and subretinal fluid predicts microglia activation involved in the breakdown of outer blood-retinal barrier in treatment-naïve patients with diabetic macular edema 高反射灶和视网膜下液预测Treatment-Naïve糖尿病黄斑水肿患者外血-视网膜屏障破坏的小胶质细胞激活。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100168
Yiyang Shu , Chaoyang Zhang , Yanlong Bi , Jingfa Zhang

Purpose

To evaluate the correlation between hyperreflective foci (HRF), the biomarker of activated microglia, and subretinal fluid (SRF), representing the dysfunction of retinal pigment epithelium (RPE), in treatment-naïve patients with diabetic macular edema (DME).

Methods

Sixty-one treatment-naïve patients (61 eyes) with DME were included in the research. Participants were divided into two categories based on the presence or absence of SRF. Basic characteristics were recorded. The parameters, including the HRF number in inner and outer retina, central macular thickness (CMT), intraretinal cyst (IRC), as well as the width, height and area of SRF, were analyzed with optical coherence tomography angiography (OCTA). The correlations between HRF and the parameters including SRF, IRC and CMT were analyzed accordingly.

Results

The mean CMT in DME with SRF group was much thicker than that in DME without SRF group (P < 0.0001). The mean HRF number in the outer retina and whole retina was markedly higher in DME patients with the presence of IRC or SRF when compared to those without IRC or SRF (P < 0.05). Further analysis showed that the width, height and area of SRF were positively correlated with the HRF number in the outer retina and the ratio of outer/whole retina HRFs (P < 0.05).

Conclusion

The positive correlation between the increased number of HRF, especially in the outer retina, and the formation of SRF in patients with DME supports the hypothesis that microglia activation represented by HRF might cause the dysfunction of RPE and the breakdown of the outer blood-retinal barrier (oBRB), which leads to the increased fluid leakage in subretinal space.
目的:评价treatment-naïve糖尿病性黄斑水肿(DME)患者视网膜色素上皮(RPE)功能障碍的生物标志物高反射灶(hyperreflective focal, HRF)与视网膜下液(subretinal fluid, SRF)之间的相关性。方法:选取DME患者61例treatment-naïve(61只眼)作为研究对象。参与者根据是否存在SRF被分为两类。记录基本特征。采用光学相干断层血管造影(OCTA)分析视网膜内外HRF数、中央黄斑厚度(CMT)、视网膜内囊肿(IRC)及SRF的宽度、高度和面积等参数。分析了HRF与SRF、IRC、CMT等参数的相关性。结果:DME合并SRF组CMT厚度明显高于DME不合并SRF组(P < 0.0001)。存在IRC或SRF的DME患者外视网膜和全视网膜的平均HRF数明显高于无IRC或SRF的患者(P < 0.05)。进一步分析发现,SRF的宽度、高度和面积与外视网膜HRF数及外视网膜/全视网膜HRF比例呈正相关(P < 0.05)。结论:DME患者HRF(尤其是外视网膜)数量的增加与SRF的形成呈正相关,支持了以HRF为代表的小胶质细胞激活可能导致RPE功能障碍和外血视网膜屏障(oBRB)的破坏,从而导致视网膜下间隙液体渗漏增加的假设。
{"title":"Hyperreflective foci and subretinal fluid predicts microglia activation involved in the breakdown of outer blood-retinal barrier in treatment-naïve patients with diabetic macular edema","authors":"Yiyang Shu ,&nbsp;Chaoyang Zhang ,&nbsp;Yanlong Bi ,&nbsp;Jingfa Zhang","doi":"10.1016/j.apjo.2025.100168","DOIUrl":"10.1016/j.apjo.2025.100168","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the correlation between hyperreflective foci (HRF), the biomarker of activated microglia, and subretinal fluid (SRF), representing the dysfunction of retinal pigment epithelium (RPE), in treatment-naïve patients with diabetic macular edema (DME).</div></div><div><h3>Methods</h3><div>Sixty-one treatment-naïve patients (61 eyes) with DME were included in the research. Participants were divided into two categories based on the presence or absence of SRF. Basic characteristics were recorded. The parameters, including the HRF number in inner and outer retina, central macular thickness (CMT), intraretinal cyst (IRC), as well as the width, height and area of SRF, were analyzed with optical coherence tomography angiography (OCTA). The correlations between HRF and the parameters including SRF, IRC and CMT were analyzed accordingly.</div></div><div><h3>Results</h3><div>The mean CMT in DME with SRF group was much thicker than that in DME without SRF group (<em>P</em> &lt; 0.0001). The mean HRF number in the outer retina and whole retina was markedly higher in DME patients with the presence of IRC or SRF when compared to those without IRC or SRF (<em>P</em> &lt; 0.05). Further analysis showed that the width, height and area of SRF were positively correlated with the HRF number in the outer retina and the ratio of outer/whole retina HRFs (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>The positive correlation between the increased number of HRF, especially in the outer retina, and the formation of SRF in patients with DME supports the hypothesis that microglia activation represented by HRF might cause the dysfunction of RPE and the breakdown of the outer blood-retinal barrier (oBRB), which leads to the increased fluid leakage in subretinal space.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100168"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International consensuses and guidelines on etiology, diagnosis, treatment, and future developments of neovascular age-related macular degeneration (nAMD) by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Ocular Imaging Society (APOIS) and the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO) 亚太玻璃体视网膜学会(APVRS)、亚太眼成像学会(APOIS)和亚太眼科教授学会(AAPPO)关于新生血管性年龄相关性黄斑变性(nAMD)的病因、诊断、治疗和未来发展的争议、共识和指南。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100242
Timothy Y.Y. Lai , Keiko Kataoka , Yi-Ting Hsieh , Rajendra S. Apte , Muna Bhende , Andrew Chang , Voraporn Chiakitmongkol , Youxin Chen , Li Jia Chen , Gemmy C.M. Cheung , Jay Chhablani , Kenneth C.S. Fong , Robyn H. Guymer , Fumi Gomi , Suber S. Huang , Judy E. Kim , Gregg T. Kokame , Adrian Koh , Xiaoxin Li , Jennifer I. Lim , Dennis S.C. Lam
Neovascular age-related degeneration (nAMD) is one of the leading causes of visual impairment in older populations in the developed world. With the aging population, the incidence of nAMD is growing globally. Despite advancements in diagnostic investigations and treatment modalities over the past three decades, there remains considerable controversies in the pathogenesis, classification and optimal management strategies. An international panel of 31 experts from 11 countries/regions prepared and voted on consensus statements in five key areas: (1) etiology controversies; (2) diagnosis controversies; (3) treatment controversies; (4) future development controversies; and (5) healthcare deliveries controversies. Among the 31 consensus statements, 28 (90.3 %) have achieved over 75 % agreement. These statements can provide a practical guide for ophthalmologists to provide the optimal care of patients with nAMD and for planning future research priorities in order to address the unmet needs in nAMD.
新生血管性年龄相关性变性(nAMD)是发达国家老年人视力损害的主要原因之一。随着人口老龄化,nAMD的发病率在全球范围内呈上升趋势。尽管在过去的三十年中,诊断调查和治疗方式取得了进步,但在发病机制、分类和最佳管理策略方面仍存在相当大的争议。一个由来自13个国家/地区的35名专家组成的国际小组就以下五个关键领域的共识声明进行了准备和投票:1)病原学争议;2)诊断争议;3)治疗争议;4)未来发展争议;5)医疗服务的争议。在31项共识声明中,达成75%以上共识的有28项(90.3%)。这些陈述可以为眼科医生提供一个实用的指导,为nAMD患者提供最佳的护理,并规划未来的研究重点,以解决nAMD未满足的需求。
{"title":"International consensuses and guidelines on etiology, diagnosis, treatment, and future developments of neovascular age-related macular degeneration (nAMD) by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Ocular Imaging Society (APOIS) and the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO)","authors":"Timothy Y.Y. Lai ,&nbsp;Keiko Kataoka ,&nbsp;Yi-Ting Hsieh ,&nbsp;Rajendra S. Apte ,&nbsp;Muna Bhende ,&nbsp;Andrew Chang ,&nbsp;Voraporn Chiakitmongkol ,&nbsp;Youxin Chen ,&nbsp;Li Jia Chen ,&nbsp;Gemmy C.M. Cheung ,&nbsp;Jay Chhablani ,&nbsp;Kenneth C.S. Fong ,&nbsp;Robyn H. Guymer ,&nbsp;Fumi Gomi ,&nbsp;Suber S. Huang ,&nbsp;Judy E. Kim ,&nbsp;Gregg T. Kokame ,&nbsp;Adrian Koh ,&nbsp;Xiaoxin Li ,&nbsp;Jennifer I. Lim ,&nbsp;Dennis S.C. Lam","doi":"10.1016/j.apjo.2025.100242","DOIUrl":"10.1016/j.apjo.2025.100242","url":null,"abstract":"<div><div>Neovascular age-related degeneration (nAMD) is one of the leading causes of visual impairment in older populations in the developed world. With the aging population, the incidence of nAMD is growing globally. Despite advancements in diagnostic investigations and treatment modalities over the past three decades, there remains considerable controversies in the pathogenesis, classification and optimal management strategies. An international panel of 31 experts from 11 countries/regions prepared and voted on consensus statements in five key areas: (1) etiology controversies; (2) diagnosis controversies; (3) treatment controversies; (4) future development controversies; and (5) healthcare deliveries controversies. Among the 31 consensus statements, 28 (90.3 %) have achieved over 75 % agreement. These statements can provide a practical guide for ophthalmologists to provide the optimal care of patients with nAMD and for planning future research priorities in order to address the unmet needs in nAMD.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100242"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Foveal actual defect (FAD): A novel OCT biomarker for prognosis and surgical decision support in idiopathic full-thickness macular hole 中央凹实际缺陷(FAD):一种新的OCT生物标志物,用于特发性全层黄斑孔的预后和手术决策支持。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100232
Andrii Ruban , Vitalyi Prudyus , Anna Zolnikova , Beáta Éva Petrovski , Goran Petrovski , Andrzej Grzybowski , Lyubomyr M. Lytvynchuk

Background

The current classification of idiopathic full thickness macular holes (IFTMH) based on the minimum linear diameter (MLD) parameter does not provide the surgeon with accurate prognostic information regarding the surgical outcome.

Purpose

To investigate whether the preoperative Foveal Actual Defect (FAD) can predict postoperative macular hole outcomes and could be a key point in new Decision Support System for IFTMHs surgery.

Patients and methods

Fifty-seven eyes of fifty-three patients with iFTMH, who underwent 25-gauge PPV, ILM peeling and gas tamponade (GT) were recruited for this retrospective, consecutive case, interventional study. The choice of additional surgical techniques was determined individually depending on the size of the FAD. Surgery outcome-related factors were also assessed.

Results

The primary closure rate was 94.7 % (54/57). Three eyes (5.3 %) with persistent MHs required an additional surgery. In all of these eyes, the MH closed after the second surgery. Mean BCVA (logMAR) significantly improved after surgery from 0.8 ± 0.3 (ME = 0.7; IQR: 0.5–1.0) to 0.1 ± 0.2; (ME = 0.1; IQR: 0.1–0.2) (P = 0.0001). There is a statistically significant difference (U = 78.0; Р = 0.05) in the preoperative FAD indicators between groups with a primary closed holes at the first day (ME = 217; IQR: 140–391) and unclosed holes (ME = 370; IQR: 222–697). The probability of MH closing by 14 days after surgery with FAD < 400 µm increases 1.3 times (RR = 1.3, 95 %CI: 1.0–1.6; φ = 0.4; P = 0.02). The MLD indicator in the primary hole closing group at first postop day did not statistically significantly different from those who did not close, but in the group with a primary closed holes at 14-th postop day the MLD indicator statistically significantly (U = 10.0; P = 0.005) was less (ME = 390; IQR: 277 – 492) compared to the unclosed holes (ME = 642; IQR: 558 – 866). There is a statistically significant correlation between postoperative BCVA at 6 month and preoperative OCT parameters: BD - ρ = 0.23 (P = 0.02), MLD - ρ = 0.34 (P = 0.005), FAD - ρ = 0.37 (P = 0.002).
The regression model showed that PreopBCVA, FAD, and BD were statistically significant: PostBCVA = 0.22 × PreBCVA + 0.00001 × BD + 0.00001 × FAD (σPreBCVA = 0.05, σBD = 0.000006, σFAD = 0.000005, R² = 0.75, P < 0.01).

Conclusion

The proposed Decision Support System based on a new preoperative OCT-parameter Foveal Actual Defect (FAD) allows a personalized assessment of macular hole surgery.
背景:目前基于最小线性直径(MLD)参数的特发性全厚度黄斑孔(IFTMH)的分类不能为外科医生提供关于手术结果的准确预后信息。目的:探讨术前中央凹实际缺损(FAD)是否能预测术后黄斑裂孔的预后,并可作为IFTMHs手术决策支持系统的关键指标。患者和方法:对53例iFTMH患者的57只眼进行回顾性、连续病例、介入性研究,这些患者接受了25号PPV、ILM剥离和气体填塞(GT)。其他手术技术的选择取决于FAD的大小。手术结果相关因素也进行了评估。结果:一期闭合率为94.7%(54/57)。3只眼(5.3%)持续性mhh需要额外手术。在所有这些眼睛中,MH在第二次手术后闭合。术后平均BCVA (logMAR)由0.8±0.3显著改善(ME = 0.7;IQR: 0.5-1.0)至0.1±0.2;(me = 0.1;Iqr: 0.1-0.2) (p = 0.0001)。差异有统计学意义(U = 78.0;第1天初闭孔组间术前FAD指标差异Р = 0.05) (ME = 217;IQR: 140-391)和未闭合孔(ME = 370;差:222 - 697)。术后14天,FAD < 400µm时MH闭合的概率增加1.3倍(RR = 1.3, 95%CI: 1.0 ~ 1.6;φ = 0.4;P = 0.02)。术后第1天初闭孔组与未闭孔组MLD指标差异无统计学意义,但术后第14天初闭孔组MLD指标差异有统计学意义(U = 10.0;P = 0.005)更少(ME = 390;IQR: 277 - 492)与未闭合孔(ME = 642;Iqr: 558 - 866)。术后6个月BCVA与术前OCT参数的相关性有统计学意义:BD - ρ = 0.23 (P = 0.02), MLD - ρ = 0.34 (P = 0.005), FAD - ρ = 0.37 (P = 0.002)。回归模型显示,PreopBCVA、FAD、BD均有统计学意义:PostBCVA = 0.22 × PreBCVA + 0.00001 × BD + 0.00001 × FAD (σPreBCVA = 0.05, σBD = 0.000006, σFAD = 0.000005, R²= 0.75,P < 0.01)。结论:提出的决策支持系统基于新的术前oct参数中央凹实际缺陷(FAD),可以对黄斑孔手术进行个性化评估。
{"title":"Foveal actual defect (FAD): A novel OCT biomarker for prognosis and surgical decision support in idiopathic full-thickness macular hole","authors":"Andrii Ruban ,&nbsp;Vitalyi Prudyus ,&nbsp;Anna Zolnikova ,&nbsp;Beáta Éva Petrovski ,&nbsp;Goran Petrovski ,&nbsp;Andrzej Grzybowski ,&nbsp;Lyubomyr M. Lytvynchuk","doi":"10.1016/j.apjo.2025.100232","DOIUrl":"10.1016/j.apjo.2025.100232","url":null,"abstract":"<div><h3>Background</h3><div>The current classification of idiopathic full thickness macular holes (IFTMH) based on the minimum linear diameter (MLD) parameter does not provide the surgeon with accurate prognostic information regarding the surgical outcome.</div></div><div><h3>Purpose</h3><div>To investigate whether the preoperative Foveal Actual Defect (FAD) can predict postoperative macular hole outcomes and could be a key point in new Decision Support System for IFTMHs surgery.</div></div><div><h3>Patients and methods</h3><div>Fifty-seven eyes of fifty-three patients with iFTMH, who underwent 25-gauge PPV, ILM peeling and gas tamponade (GT) were recruited for this retrospective, consecutive case, interventional study. The choice of additional surgical techniques was determined individually depending on the size of the FAD. Surgery outcome-related factors were also assessed.</div></div><div><h3>Results</h3><div>The primary closure rate was 94.7 % (54/57). Three eyes (5.3 %) with persistent MHs required an additional surgery. In all of these eyes, the MH closed after the second surgery. Mean BCVA (logMAR) significantly improved after surgery from 0.8 ± 0.3 (ME = 0.7; IQR: 0.5–1.0) to 0.1 ± 0.2; (ME = 0.1; IQR: 0.1–0.2) (<em>P</em> = 0.0001). There is a statistically significant difference (U = 78.0; <em>Р</em> = 0.05) in the preoperative FAD indicators between groups with a primary closed holes at the first day (ME = 217; IQR: 140–391) and unclosed holes (ME = 370; IQR: 222–697). The probability of MH closing by 14 days after surgery with FAD &lt; 400 µm increases 1.3 times (RR = 1.3, 95 %CI: 1.0–1.6; φ = 0.4; <em>P</em> = 0.02). The MLD indicator in the primary hole closing group at first postop day did not statistically significantly different from those who did not close, but in the group with a primary closed holes at 14-th postop day the MLD indicator statistically significantly (U = 10.0; <em>P</em> = 0.005) was less (ME = 390; IQR: 277 – 492) compared to the unclosed holes (ME = 642; IQR: 558 – 866). There is a statistically significant correlation between postoperative BCVA at 6 month and preoperative OCT parameters: BD - ρ = 0.23 (<em>P</em> = 0.02), MLD - ρ = 0.34 (<em>P</em> = 0.005), FAD - ρ = 0.37 (<em>P</em> = 0.002).</div><div>The regression model showed that PreopBCVA, FAD, and BD were statistically significant: PostBCVA = 0.22 × PreBCVA + 0.00001 × BD + 0.00001 × FAD (σPreBCVA = 0.05, σBD = 0.000006, σFAD = 0.000005, R² = 0.75, <em>P</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>The proposed Decision Support System based on a new preoperative OCT-parameter Foveal Actual Defect (FAD) allows a personalized assessment of macular hole surgery.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100232"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII) 亚太玻璃体视网膜学会(APVRS)、亚太眼科教授学会(AAPPO)和亚太眼部炎症与感染学会(APSOII)就巨细胞病毒(CMV)视网膜炎的诊断和治疗达成国际共识和指南。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100248
De-Kuang Hwang , Danny S.C. Ng , Zhuyun Qian , Rupesh Agrawal , Anita S.Y. Chan , Jay Chhablani , Pitipol Choopong , Vishali Gupta , Alessandro Invernizzi , Peter McCluskey , Christopher Seungkyu Lee , Sundaram Natarajan , Rina La Distia Nora , Vicente Victor Ocampo Jr , Ramandeep Singh , Thanapong Somkijrungroj , Koh-Hei Sonoda , Wenbin Wei , Ian Y.H. Wong , Dennis S.C. Lam , Yong Tao
With the paradigm changes in antiviral therapy, there are a myriad of emerging controversies in the management of cytomegalovirus retinitis (CMVR). A certain extent of variability exists in the management of CMVR among clinical practices worldwide. Hence, alignment in the management strategy is important towards optimizing the care of CMVR. An international panel of experts (IPE) formulated consensus statements for CMVR regarding to its 1) diagnosis, 2) screening, 3) treatment, 4) management in special populations and 5) emerging technologies. The clinical diagnosis of CMVR relies on patient’s susceptibility due to compromised immune function and characteristic fundus manifestations. Polymerase chain reaction (PCR) of intraocular fluid for detection of CMV is indicated when confirmation is necessary. Oral valganciclovir is the preferred first-line treatment, and intravitreal ganciclovir injection when CMVR threatens to involve the posterior pole. Cessation of maintenance treatment can be considered after 6 months when CMVR remains inactive with immune reconstitution. Immune recovery uveitis (IRU) must be distinguished from CMVR relapse. Screening is recommended for high risk cases. Utilization of telemedicine and artificial intelligence-aided interpretation will help to alleviate the resources required for CMVR screening. Evidence for novel antiviral and immunotherapy have been appraised as second-line treatment options.
随着抗病毒治疗模式的改变,巨细胞病毒性视网膜炎(CMVR)的治疗出现了无数新的争议。在全球临床实践中,CMVR的管理存在一定程度的可变性。因此,管理策略的一致性对于优化CMVR的护理非常重要。国际专家小组(IPE)就CMVR的1)诊断、2)筛查、3)治疗、4)特殊人群管理和5)新兴技术制定了共识声明。CMVR的临床诊断依赖于患者因免疫功能受损和特征性眼底表现而产生的易感性。当确认有必要时,可用眼内液聚合酶链反应(PCR)检测巨细胞病毒。口服缬更昔洛韦是首选的一线治疗,当CMVR威胁累及后极时,玻璃体内注射更昔洛韦。6个月后,当CMVR仍无活性且免疫重建时,可考虑停止维持治疗。免疫恢复性葡萄膜炎(IRU)必须与CMVR复发相鉴别。建议对高危病例进行筛查。利用远程医疗和人工智能辅助解释将有助于减轻CMVR筛查所需的资源。有证据表明,新的抗病毒和免疫疗法可作为二线治疗选择。
{"title":"International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII)","authors":"De-Kuang Hwang ,&nbsp;Danny S.C. Ng ,&nbsp;Zhuyun Qian ,&nbsp;Rupesh Agrawal ,&nbsp;Anita S.Y. Chan ,&nbsp;Jay Chhablani ,&nbsp;Pitipol Choopong ,&nbsp;Vishali Gupta ,&nbsp;Alessandro Invernizzi ,&nbsp;Peter McCluskey ,&nbsp;Christopher Seungkyu Lee ,&nbsp;Sundaram Natarajan ,&nbsp;Rina La Distia Nora ,&nbsp;Vicente Victor Ocampo Jr ,&nbsp;Ramandeep Singh ,&nbsp;Thanapong Somkijrungroj ,&nbsp;Koh-Hei Sonoda ,&nbsp;Wenbin Wei ,&nbsp;Ian Y.H. Wong ,&nbsp;Dennis S.C. Lam ,&nbsp;Yong Tao","doi":"10.1016/j.apjo.2025.100248","DOIUrl":"10.1016/j.apjo.2025.100248","url":null,"abstract":"<div><div>With the paradigm changes in antiviral therapy, there are a myriad of emerging controversies in the management of cytomegalovirus retinitis (CMVR). A certain extent of variability exists in the management of CMVR among clinical practices worldwide. Hence, alignment in the management strategy is important towards optimizing the care of CMVR. An international panel of experts (IPE) formulated consensus statements for CMVR regarding to its 1) diagnosis, 2) screening, 3) treatment, 4) management in special populations and 5) emerging technologies. The clinical diagnosis of CMVR relies on patient’s susceptibility due to compromised immune function and characteristic fundus manifestations. Polymerase chain reaction (PCR) of intraocular fluid for detection of CMV is indicated when confirmation is necessary. Oral valganciclovir is the preferred first-line treatment, and intravitreal ganciclovir injection when CMVR threatens to involve the posterior pole. Cessation of maintenance treatment can be considered after 6 months when CMVR remains inactive with immune reconstitution. Immune recovery uveitis (IRU) must be distinguished from CMVR relapse. Screening is recommended for high risk cases. Utilization of telemedicine and artificial intelligence-aided interpretation will help to alleviate the resources required for CMVR screening. Evidence for novel antiviral and immunotherapy have been appraised as second-line treatment options.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100248"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controversy and consensus on the management of ocular toxoplasmosis: A joint statement by the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII), the Asia-Pacific Vitreo-Retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and The Infectious Uveitis Treatment Algorithm Network (TITAN) Group 眼弓形虫病治疗的争议与共识:亚太眼炎症与感染学会(APSOII)、亚太玻璃体视网膜学会(APVRS)、亚太眼科教授学会(AAPPO)和感染性葡萄膜炎治疗算法网络(TITAN)小组的联合声明。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100244
Ikhwanuliman Putera , Carlos Cifuentes-González , William Rojas-Carabali , Zheng Xian Thng , Sivaraman Bala Murugan , Rachel Song , Liang Yao , Rubens Belfort Jr. , Andre Curi , Nicholas Jones , Jennifer E. Thorne , Rina La Distia Nora , Alejandra de-la-Torre , Rupesh Agrawal , on behalf of TITAN consensus guidelines group
This international consensus effort, convened by The Infectious Uveitis Treatment Algorithm Network (TITAN) group, brought together 103 uveitis experts to address long-standing controversies in the management of ocular toxoplasmosis (OT), a leading cause of infectious posterior uveitis worldwide. Despite the availability of advanced diagnostic tools, variability persists in clinical decision-making. Controversies were identified from previous surveys on OT management, which served as the foundation for developing the survey questions in this study. Using a two-round modified Delphi method, experts reviewed evidence and rated recommendations across three domains: diagnosis and investigations, treatment, and follow-up management. Key consensus findings include support for antiparasitic therapy in most active cases, selective use of polymerase chain reaction (PCR) testing for atypical presentations, and prophylactic therapy in high-risk scenarios. These expert-derived consensus provide a framework for best practices in OT clinical management and highlight priorities for future prospective studies.
由传染性葡萄膜炎治疗算法网络(TITAN)小组召集的这项国际共识努力汇集了103名葡萄膜炎专家,以解决长期存在的关于眼弓形虫病(OT)管理的争议,OT是世界范围内传染性后葡萄膜炎的主要原因。尽管有先进的诊断工具,但临床决策的可变性仍然存在。争议是从以前的调查中发现的,这是本研究中调查问题的基础。使用两轮改进的德尔菲法,专家们审查了三个领域的证据并对建议进行了评级:诊断和调查、治疗和随访管理。关键的共识发现包括支持对大多数活动性病例进行抗寄生虫治疗,对非典型症状选择性使用聚合酶链反应(PCR)检测,以及在高危情况下进行预防性治疗。这些专家衍生的共识为OT临床管理的最佳实践提供了框架,并强调了未来前瞻性研究的优先事项。
{"title":"Controversy and consensus on the management of ocular toxoplasmosis: A joint statement by the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII), the Asia-Pacific Vitreo-Retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and The Infectious Uveitis Treatment Algorithm Network (TITAN) Group","authors":"Ikhwanuliman Putera ,&nbsp;Carlos Cifuentes-González ,&nbsp;William Rojas-Carabali ,&nbsp;Zheng Xian Thng ,&nbsp;Sivaraman Bala Murugan ,&nbsp;Rachel Song ,&nbsp;Liang Yao ,&nbsp;Rubens Belfort Jr. ,&nbsp;Andre Curi ,&nbsp;Nicholas Jones ,&nbsp;Jennifer E. Thorne ,&nbsp;Rina La Distia Nora ,&nbsp;Alejandra de-la-Torre ,&nbsp;Rupesh Agrawal ,&nbsp;on behalf of TITAN consensus guidelines group","doi":"10.1016/j.apjo.2025.100244","DOIUrl":"10.1016/j.apjo.2025.100244","url":null,"abstract":"<div><div>This international consensus effort, convened by <strong>The Infectious Uveitis Treatment Algorithm Network (</strong>TITAN) group, brought together 103 uveitis experts to address long-standing controversies in the management of ocular toxoplasmosis (OT), a leading cause of infectious posterior uveitis worldwide. Despite the availability of advanced diagnostic tools, variability persists in clinical decision-making. Controversies were identified from previous surveys on OT management, which served as the foundation for developing the survey questions in this study. Using a two-round modified Delphi method, experts reviewed evidence and rated recommendations across three domains: diagnosis and investigations, treatment, and follow-up management. Key consensus findings include support for antiparasitic therapy in most active cases, selective use of polymerase chain reaction (PCR) testing for atypical presentations, and prophylactic therapy in high-risk scenarios. These expert-derived consensus provide a framework for best practices in OT clinical management and highlight priorities for future prospective studies.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100244"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Panretinal photocoagulation during vitrectomy for diabetic vitreous hemorrhage: A clinical trial comparing endolaser application amounts 玻璃体切除术治疗糖尿病玻璃体出血的全视网膜光凝:一项比较激光应用量的临床试验。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100197
Ryan B. Rush , Pedro Luis Gomez , Pedro Gomez Bastar , Sloan W. Rush

Purpose

To evaluate the effectiveness of different endolaser photocoagulation treatment amounts during pars plana vitrectomy (PPV) in patients with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).

Design

Randomized clinical trial

Methods

One hundred and forty-four treatment-naïve PDR patients with an ocular media-obscuring VH were enrolled into this clinical trial. Participants were randomized into one of two possible treatment groups: Group A subjects underwent PPV and received 250 + /- 50 endolaser applications during surgery, while Group B subjects underwent PPV and received 550 + /- 50 endolaser applications during surgery. The primary outcome was the rate of postoperative VH, and the secondary outcome was visual acuity at 6 months.

Results

Ninety-one patients underwent PPV and completed the 6-month trial period. Group A had 30.0 % (15/50) of participants develop a postoperative VH, while Group B had 12.2 % (5/41) of subjects develop a postoperative VH at 6 months (P = 0.002). The visual acuity of 0.4 (0.23–0.57) logMAR (Snellen 20/50) in Group B was better than that of 0.79 (0.58–1.01) logMAR (Snellen 20/120) in Group A at the end of the 6 month trial period (P = 0.006).

Conclusions

Treatment-naïve PDR subjects undergoing PPV for an ocular media-obscuring VH have a lower incidence of postoperative VH and better visual acuity at 6 months when 550 + /- 50 endolaser applications were administered compared to 250 + /- 50 endolaser applications during PPV. Further research is warranted on this topic to verify the generalizability of these findings to a broader PDR population.
目的:评价增殖性糖尿病视网膜病变(PDR)继发玻璃体出血(VH)玻璃体切除术(PPV)中不同剂量内激光光凝治疗的效果。设计:随机临床试验方法:144例treatment-naïve PDR伴眼介质模糊VH患者入组本临床试验。参与者被随机分为两个可能的治疗组之一:A组患者接受PPV治疗,手术期间接受250次 + /- 50次内激光照射,而B组患者接受PPV治疗,手术期间接受550次 + /- 50次内激光照射。主要观察指标为术后VH发生率,次要观察指标为术后6个月视力。结果:91例患者接受了PPV治疗,完成了6个月的临床试验。A组术后VH发生率为30.0 % (15/50),B组术后6个月VH发生率为12.2 % (5/41)(P = 0.002)。6个月试验期结束时,B组的视力为0.4 (0.23-0.57)logMAR (Snellen 20/50)优于A组的0.79 (0.58-1.01)logMAR (Snellen 20/120) (P = 0.006)。结论:Treatment-naïve PDR患者在PPV期间接受550次 + /- 50次激光治疗,相比于250次 + /- 50次激光治疗,术后VH发生率较低,6个月时视力更好。有必要对这一主题进行进一步研究,以验证这些发现在更广泛的PDR人群中的普遍性。
{"title":"Panretinal photocoagulation during vitrectomy for diabetic vitreous hemorrhage: A clinical trial comparing endolaser application amounts","authors":"Ryan B. Rush ,&nbsp;Pedro Luis Gomez ,&nbsp;Pedro Gomez Bastar ,&nbsp;Sloan W. Rush","doi":"10.1016/j.apjo.2025.100197","DOIUrl":"10.1016/j.apjo.2025.100197","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the effectiveness of different endolaser photocoagulation treatment amounts during pars plana vitrectomy (PPV) in patients with a vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).</div></div><div><h3>Design</h3><div>Randomized clinical trial</div></div><div><h3>Methods</h3><div>One hundred and forty-four treatment-naïve PDR patients with an ocular media-obscuring VH were enrolled into this clinical trial. Participants were randomized into one of two possible treatment groups: Group A subjects underwent PPV and received 250 + /- 50 endolaser applications during surgery, while Group B subjects underwent PPV and received 550 + /- 50 endolaser applications during surgery. The primary outcome was the rate of postoperative VH, and the secondary outcome was visual acuity at 6 months.</div></div><div><h3>Results</h3><div>Ninety-one patients underwent PPV and completed the 6-month trial period. Group A had 30.0 % (15/50) of participants develop a postoperative VH, while Group B had 12.2 % (5/41) of subjects develop a postoperative VH at 6 months (<em>P</em> = 0.002). The visual acuity of 0.4 (0.23–0.57) logMAR (Snellen 20/50) in Group B was better than that of 0.79 (0.58–1.01) logMAR (Snellen 20/120) in Group A at the end of the 6 month trial period (<em>P</em> = 0.006).</div></div><div><h3>Conclusions</h3><div>Treatment-naïve PDR subjects undergoing PPV for an ocular media-obscuring VH have a lower incidence of postoperative VH and better visual acuity at 6 months when 550 + /- 50 endolaser applications were administered compared to 250 + /- 50 endolaser applications during PPV. Further research is warranted on this topic to verify the generalizability of these findings to a broader PDR population.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100197"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI) 亚太玻璃体视网膜学会(APVRS)、亚太眼科教授学会(AAPPO)和国际视网膜学会(ARI)就中心性浆液性脉络膜视网膜病变(CSC)达成国际共识和指南。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100252
Nishant V. Radke , Elon H.C. van Dijk , Richard F. Spaide , Frank G. Holz , Hideki Koizumi , K. Bailey Freund , Yousif Subhi , Clemens Lange , Sumit Randhir Singh , Haoyu Chen , Li Jia Chen , San-Ni Chen , Jay Chhablani , Francine Behar-Cohen , Taraprasad Das , Adrian T. Fung , Fumi Gomi , Min Kim , Chi-Chun Lai , Timothy Y.Y. Lai , Camiel J.F. Boon

Purpose

To establish consensus-based guidelines on the diagnosis, classification, and management of central serous chorioretinopathy (CSC) through a structured expert panel initiated by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and the Academia Retina Internationalis (ARI), addressing the existing clinical controversies.

Methods

An international panel of 26 experts from 13 countries collaboratively drafted consensus statements spanning five key areas: disease definition, pathophysiology, investigations, current management, and future developments. Consensus was reached through an iterative Delphi process and anonymous voting using a five-point Likert scale. Statements were accepted when >75 % agreement (‘agree’ & ‘strongly agree’) was achieved.

Results

Consensus was achieved for all 25 statements, reflecting strong alignment among experts. Key agreements included defining CSC as a pachychoroid-driven chorioretinal disorder characterized by neurosensory retinal and/or RPE detachment, with multimodal imaging (optical coherence tomography, fundus autofluorescence, fluorescein angiography, and indocyanine green angiography) recognized as essential for diagnosis. Half-dose photodynamic therapy (PDT) was unanimously endorsed as the first-line treatment for chronic CSC. Oral mineralocorticoid receptor antagonists (MRAs) lacked consensus for therapeutic benefit, aligning with evidence from the VICI and SPECTRA trials. Anti-vascular endothelial growth factor receptor therapy was recommended solely for CSC complicated by a macular neovascularization. Future priorities highlighted standardizing disease classification and exploring targeted therapies through genetic and nanomedicine research.

Conclusion

This consensus initiative provides a robust, evidence-based framework for the diagnosis and management of CSC, promoting standardization across clinical practices and guiding future research directions to address persistent gaps in CSC care.
目的:通过亚太玻璃体视网膜学会(APVRS)和亚太眼科教授学会(AAPPO)的专家小组倡议,建立基于共识的中枢性浆液性脉络膜视网膜病变(CSC)的诊断、分类和治疗指南,解决现有的临床争议。方法:由来自13个国家的26名专家组成的国际小组共同起草了共识声明,涵盖5个关键领域:疾病定义、病理生理学、调查、当前管理和未来发展。通过反复德尔菲过程和使用五点李克特量表的匿名投票达成共识。当达到≥75%的同意(“同意”和“非常同意”)时,陈述被接受。结果:29项声明中有28项达成共识(96.6%),反映了专家之间的强烈一致性。关键协议包括将CSC定义为以神经感觉视网膜和/或RPE脱离为特征的厚脉络膜驱动的脉络膜视网膜疾病,多模态成像(光学相干断层扫描、眼底自身荧光、荧光素血管造影和吲吲吲胺绿血管造影)被认为是诊断的必要条件。半剂量光动力疗法(PDT)被一致认可为慢性CSC的一线治疗方法。口服矿皮质激素受体拮抗剂(MRAs)的治疗效果缺乏共识,与VICI和SPECTRA试验的证据一致。抗血管内皮生长因子受体治疗被推荐仅用于CSC合并黄斑新生血管。未来的重点是通过遗传和纳米医学研究标准化疾病分类和探索靶向治疗。结论:这一共识倡议为CSC的诊断和管理提供了一个强有力的、基于证据的框架,促进了临床实践的标准化,并指导了未来的研究方向,以解决CSC护理中持续存在的差距。
{"title":"International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI)","authors":"Nishant V. Radke ,&nbsp;Elon H.C. van Dijk ,&nbsp;Richard F. Spaide ,&nbsp;Frank G. Holz ,&nbsp;Hideki Koizumi ,&nbsp;K. Bailey Freund ,&nbsp;Yousif Subhi ,&nbsp;Clemens Lange ,&nbsp;Sumit Randhir Singh ,&nbsp;Haoyu Chen ,&nbsp;Li Jia Chen ,&nbsp;San-Ni Chen ,&nbsp;Jay Chhablani ,&nbsp;Francine Behar-Cohen ,&nbsp;Taraprasad Das ,&nbsp;Adrian T. Fung ,&nbsp;Fumi Gomi ,&nbsp;Min Kim ,&nbsp;Chi-Chun Lai ,&nbsp;Timothy Y.Y. Lai ,&nbsp;Camiel J.F. Boon","doi":"10.1016/j.apjo.2025.100252","DOIUrl":"10.1016/j.apjo.2025.100252","url":null,"abstract":"<div><h3>Purpose</h3><div>To establish consensus-based guidelines on the diagnosis, classification, and management of central serous chorioretinopathy (CSC) through a structured expert panel initiated by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and the Academia Retina Internationalis (ARI), addressing the existing clinical controversies.</div></div><div><h3>Methods</h3><div>An international panel of 26 experts from 13 countries collaboratively drafted consensus statements spanning five key areas: disease definition, pathophysiology, investigations, current management, and future developments. Consensus was reached through an iterative Delphi process and anonymous voting using a five-point Likert scale. Statements were accepted when &gt;75 % agreement (‘agree’ &amp; ‘strongly agree’) was achieved.</div></div><div><h3>Results</h3><div>Consensus was achieved for all 25 statements, reflecting strong alignment among experts. Key agreements included defining CSC as a pachychoroid-driven chorioretinal disorder characterized by neurosensory retinal and/or RPE detachment, with multimodal imaging (optical coherence tomography, fundus autofluorescence, fluorescein angiography, and indocyanine green angiography) recognized as essential for diagnosis. Half-dose photodynamic therapy (PDT) was unanimously endorsed as the first-line treatment for chronic CSC. Oral mineralocorticoid receptor antagonists (MRAs) lacked consensus for therapeutic benefit, aligning with evidence from the VICI and SPECTRA trials. Anti-vascular endothelial growth factor receptor therapy was recommended solely for CSC complicated by a macular neovascularization. Future priorities highlighted standardizing disease classification and exploring targeted therapies through genetic and nanomedicine research.</div></div><div><h3>Conclusion</h3><div>This consensus initiative provides a robust, evidence-based framework for the diagnosis and management of CSC, promoting standardization across clinical practices and guiding future research directions to address persistent gaps in CSC care.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100252"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-inverted and single-layer “plastic bag” ILM flap novel technique to treat large macular holes 非倒置单层“塑料袋”ILM瓣治疗黄斑大孔的新技术。
IF 4.5 3区 医学 Q1 OPHTHALMOLOGY Pub Date : 2025-09-01 DOI: 10.1016/j.apjo.2025.100164
Tian Tian , Dian Jiao , Xiang Zhang, Mingyang Wang, Shipeng Guo, Jiao Lyu, Peiquan Zhao

Purpose

To assess the efficacy and safety of a novel non-inverted, free single-layer internal limiting membrane (ILM) flap technique for treating large full-thickness macular holes (FTMHs).

Methods

Patients with FTMHs underwent a standard 3-port pars plana vitrectomy using the 23-gauge vitrectomy system. Unique to this technique, a “tongue-shaped” ILM flap was initially created, followed by the formation of two “handles” and the bottom of “plastic bag” ILM flaps. Under perfluoro-n-octane (PFO), the two-point fixed “plastic bag” ILM flap was transferred to the free flap and dragged to cover MH using the ocular viscoelastic device (OVD) to cover the margin of the ILM flap, followed by gas tamponade. Preoperative and postoperative assessments included best-corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT).

Results

The 13 patients (mean age 64.38 ± 8.08 years, macular diameter 664.85 ± 153.38μm) demonstrated a significant improvement in BCVA from 1.03 ± 0.22 logMAR preoperatively to 0.78 ± 0.26 logMAR postoperatively (P = 0.0004). In all cases, successful closure of the MH was accomplished, including 10 (76.92 %) U-shaped closure, 1 (7.69 %) flat closure, 1 (7.69 %) W-shaped closure, 1 (7.69 %) flap closure, with no ILM flap dislocations.

Conclusions

The non-inverted single-layer “plastic bag” ILM flap technique has been demonstrated to be both a safe and effective method for managing large FTMHs, offering a promising alternative to traditional methods with improved anatomical restorations and stable visual outcomes.
目的:评价一种新型非倒置自由单层内限制膜(ILM)瓣技术治疗大面积全层黄斑裂孔(FTMHs)的疗效和安全性。方法:采用23号玻璃体切割系统对FTMHs患者行标准的三孔玻璃体切割。这项技术的独特之处在于,最初创造了一个“舌形”的ILM皮瓣,然后形成两个“手柄”和“塑料袋”ILM皮瓣的底部。在全氟辛烷(PFO)下,使用眼粘弹性装置(OVD)覆盖ILM瓣边缘,将定点固定的“塑料袋”ILM瓣转移到自由瓣上,拖动覆盖MH,然后进行气体填塞。术前和术后评估包括最佳矫正视力(BCVA)和光谱域光学相干断层扫描(SD-OCT)。结果:13例患者(平均年龄64.38±8.08岁,黄斑直径664.85±153.38μm) BCVA由术前的1.03±0.22 logMAR改善至术后的0.78±0.26 logMAR (P = 0.0004)。所有病例均成功完成MH闭合,其中u形闭合10例(76.92%),平形闭合1例(7.69%),w形闭合1例(7.69%),皮瓣闭合1例(7.69%),无ILM皮瓣脱位。结论:非倒置单层“塑料袋”ILM皮瓣技术已被证明是一种安全有效的治疗大型FTMHs的方法,为传统方法提供了一种有希望的替代方法,具有改善的解剖修复和稳定的视觉效果。
{"title":"Non-inverted and single-layer “plastic bag” ILM flap novel technique to treat large macular holes","authors":"Tian Tian ,&nbsp;Dian Jiao ,&nbsp;Xiang Zhang,&nbsp;Mingyang Wang,&nbsp;Shipeng Guo,&nbsp;Jiao Lyu,&nbsp;Peiquan Zhao","doi":"10.1016/j.apjo.2025.100164","DOIUrl":"10.1016/j.apjo.2025.100164","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the efficacy and safety of a novel non-inverted, free single-layer internal limiting membrane (ILM) flap technique for treating large full-thickness macular holes (FTMHs).</div></div><div><h3>Methods</h3><div>Patients with FTMHs underwent a standard 3-port pars plana vitrectomy using the 23-gauge vitrectomy system. Unique to this technique, a “tongue-shaped” ILM flap was initially created, followed by the formation of two “handles” and the bottom of “plastic bag” ILM flaps. Under perfluoro-n-octane (PFO), the two-point fixed “plastic bag” ILM flap was transferred to the free flap and dragged to cover MH using the ocular viscoelastic device (OVD) to cover the margin of the ILM flap, followed by gas tamponade. Preoperative and postoperative assessments included best-corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT).</div></div><div><h3>Results</h3><div>The 13 patients (mean age 64.38 ± 8.08 years, macular diameter 664.85 ± 153.38μm) demonstrated a significant improvement in BCVA from 1.03 ± 0.22 logMAR preoperatively to 0.78 ± 0.26 logMAR postoperatively (<em>P</em> = 0.0004). In all cases, successful closure of the MH was accomplished, including 10 (76.92 %) U-shaped closure, 1 (7.69 %) flat closure, 1 (7.69 %) W-shaped closure, 1 (7.69 %) flap closure, with no ILM flap dislocations.</div></div><div><h3>Conclusions</h3><div>The non-inverted single-layer “plastic bag” ILM flap technique has been demonstrated to be both a safe and effective method for managing large FTMHs, offering a promising alternative to traditional methods with improved anatomical restorations and stable visual outcomes.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 5","pages":"Article 100164"},"PeriodicalIF":4.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asia-Pacific Journal of Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1